Comparison of generic and lung cancer-specific quality of life instruments for predictive ability of survival in patients with advanced lung cancer

Göksel, Tuncay; Erbaycu, Ahmet Emin; Baydur, Hakan; Basarik, Burcu; Yanık, Ayşen Öz; Gürsul, Kader Kıyar; Çeli̇k, Pınar; Ediz, Ebru Çakir; Hatipoğlu, Osman Nuri; Yayla, Bedriye Atay; Baser, Sevin; Eser, Erhan

doi:10.1186/s40064-016-3492-7

Cited by 11 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These symptoms may increase anxiety and depression in patients. The most common and significant toxicities are hematologic and gastrointestinal (25,26) . In this study, the most frequent toxicity types were same.…”

Section: Discussionmentioning

confidence: 99%

The Impact of Chemotherapy on the EORTC QLQ-C30 and LC-13 Quality of Life Scales in Patients with Lung Cancer

Güvençli¹,

Yalnız²,

Kömürcüoğlu³

et al. 2021

Terh

Self Cite

View full text Add to dashboard Cite

Objective: The concept of quality of life (QoL) in lung cancer includes many physical, psychological and social components. We aimed to assess the effect of chemotherapy (CT) on QoL of lung cancer patients using QoL scales. Methods: Fifty inoperable lung cancer patients who were newly diagnosed and taken into a CT plan were included. Patients were followed in terms of responsiveness and toxicity. Turkish versions of the EORTC QLQ-C30 and LC13 scales were used before every cycles. Results: The average age was 60.1 years. There was no difference between QoL and age/income levels. The assessment of physical, social and occupational functions and overall health status of the male patients was better than female. Overall health status without comorbidity was better in the first cycle CT. Chemotherapy led to deterioration in social functions and economic status together with increase in neuropathy, constipation and hair loss. Patients with complete or partial response to treatment were observed to have better physical, occupational, emotional, cognitive and social functions, economic status and overall health; less fatigue, pain, shortness of breath, neuropathy and better appetite. Toxicities were found to affect the QLQ C30 and LC13 scales adversely. Conclusion: Presence of comorbidity, low education levels, socioeconomic status and CT induced hematologic/gastrointestinal toxicities are the major parameters affect QOL in lung cancer. Chemotherapy leads to deterioration in social functions, increase in adverse events as well as worsening in economic status. Radiologic complete or partial response and small cell carcinoma are states in which parameters of QoL are affected positively by chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

The Impact of Chemotherapy on the EORTC QLQ-C30 and LC-13 Quality of Life Scales in Patients with Lung Cancer

Güvençli¹,

Yalnız²,

Kömürcüoğlu³

et al. 2021

Terh

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a study that enrolled patients regardless of their disease stage and histological subtype, the prognostic impact of the FACT-G total score was not significant, but only that of the PWB score was significant [26]. Other studies performed with patients in stages III and IV have shown conflicting results [25,36].…”

Section: Discussionmentioning

confidence: 94%

Prognostic Value of Functional Assessment of Cancer Therapy-General (FACT-G) in Advanced Non-Small-Cell Lung Cancer Treated with Korean Medicine

Jeon

Shim

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objectives. The impact of health-related quality of life (HRQoL) on survival has been investigated in patients with various cancers. Here, we evaluated the prognostic value of HRQoL using the Functional Assessment of Cancer Therapy-General (FACT-G) in advanced non-small-cell lung cancer (NSCLC) patients treated with Korean medicine. Methods. A retrospective review of medical records and FACT-G scores of patients with advanced NSCLC who received treatment with Korean medicine was conducted. The reliability of the FACT-G was determined using Cronbach’s alpha and calculating floor-and-ceiling effects. Correlations between FACT-G scores were estimated using Pearson’s correlation analysis. Overall survival was calculated using the Kaplan–Meier method, and the prognostic impact of FACT-G scores and patients’ characteristics was evaluated with Cox proportional hazards regression. Results. Of the 165 enrolled patients, 115 (70%) had extrathoracic metastasis and 139 (84%) had undergone prior anticancer treatment. The median overall survival was 10.1 months. The mean FACT-G score was 65.0, and Cronbach’s alpha for the FACT-G was 0.917. Age ≥65 years, male sex, smoking history, squamous-cell carcinoma, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≥2, and presence of extrathoracic metastasis were associated with an increased risk of mortality. High FACT-G total scores, physical well-being (PWB), emotional well-being, and functional well-being were associated with prolonged survival. After adjusting for age, sex, smoking history, ECOG-PS, histological type, and presence of extrathoracic metastasis, a high FACT-G total score (hazard ratio (HR): 0.99, p=0.032) and high PWB score (HR: 0.94, p<0.001) were associated with prolonged survival as independent prognostic factors in patients with advanced NSCLC. Conclusion. The FACT-G total score and PWB score as HRQoL measurements were significant prognostic factors for survival in advanced NSCLC patients treated with Korean medicine. This finding implies that the FACT-G can be used in clinical practice as a predictor of survival in patients with advanced NSCLC.

show abstract

“…Bu hasta grubunda uyku kalitesi ile ilgili önlemlerin ve gereken olgularda tedavilerin yaşam kalitesi ve prognoz üzerine olumlu etkileri olabilir. Akciğer kanserli hastalarda yaşam kalitesinin prognozu öngörebildiği de belirtilmektedir (10) .…”

Section: Discussionunclassified

Akciğer Kanserinin ve Kemoterapinin Uyku ve Yaşam Kalitesi Üzerine Etkisi

Kızılırmak¹,

Göktalay²,

Gültekin³

et al. 2021

IGH

Self Cite

View full text Add to dashboard Cite

Objective: Lung cancer affects the quality of sleep and life depending on both local and systemic impacts. Chemotherapy that is frequently used in the treatment of lung cancer can affect quality of sleep and life due to disease response, side effects of chemotherapy, systemic effects due to chemotherapeutic agents and complications of immunosuppression. The sleep and life quality levels of patients with locally advanced and metastatic stage lung cancer and the effect of chemotherapy on sleep and quality of life in this patient group were investigated in this study. Method: The Pittsburg Sleep Quality Index and the EORTC QLQ-C30 Cancer Patients’ Quality of Life Scale were applied to the patients who received chemotherapy alone with diagnosis of locally advanced and metastatic stage lung cancer at the time of diagnosis and after the third course of chemotherapy to evaluate sleep quality and quality of life. The mean age of the patients was 61.85 (± 6.80) and 89.8% of them were male. 69.5% of all patients had poor sleep quality at the time of diagnosis. Physical function was found to be affected the most in terms of functional parameters. The symptoms that most affected the quality of life were fatigue and dyspnea. Results: A significant correlation was observed between sleep quality and quality of life at the time of diagnosis in patients with lung cancer, but no significant change was found in sleep quality in the early period after chemotherapy. There was a statistically weak worsening in social functions and nausea symptom after chemotherapy and a statistically significant worsening in the malaise symptom when the quality of life scores were evaluated. Other quality of life parameters were generally similar to those before treatment. Conclusion: In conclusion, while chemotherapy does not make a significant change in the sleep quality of patients in the early period in patients with lung cancer, it may negatively affect the quality of life.

show abstract

Comparison of generic and lung cancer-specific quality of life instruments for predictive ability of survival in patients with advanced lung cancer

Cited by 11 publications

References 37 publications

The Impact of Chemotherapy on the EORTC QLQ-C30 and LC-13 Quality of Life Scales in Patients with Lung Cancer

The Impact of Chemotherapy on the EORTC QLQ-C30 and LC-13 Quality of Life Scales in Patients with Lung Cancer

Prognostic Value of Functional Assessment of Cancer Therapy-General (FACT-G) in Advanced Non-Small-Cell Lung Cancer Treated with Korean Medicine

Akciğer Kanserinin ve Kemoterapinin Uyku ve Yaşam Kalitesi Üzerine Etkisi

Contact Info

Product

Resources

About